ALEC

Alector’s updated analyst framework now points to a fair value move from US$2.88 to US$3.10, a modest shift that still signals a meaningful recalibration of expectations. This change is closely tied to how analysts are weighing CELIA’s readthrough for tau-targeting therapies and Alector’s pivot toward blood brain barrier shuttle based designs, balancing the scientific promise against execution risks and the memory of prior trial setbacks. As you read on, you will see how to track these moving...

Alector’s updated analyst framework now points to a fair value move from US$2.88 to US$3.10, a modest shift that still signals a meaningful recalibration of expectations. This change is closely tied to how analysts are weighing CELIA’s readthrough for tau-targeting therapies and Alector’s pivot toward blood brain barrier shuttle based designs, balancing the scientific promise against execution risks and the memory of prior trial setbacks. As you read on, you will see how to track these moving...

Alector (ALEC) delivered earnings and revenue surprises of +40.00% and -65.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) delivered earnings and revenue surprises of +40.00% and -65.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer’s disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) $206.5 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Cali

$125,000,000Common StockWe have entered into a sales agreement with TD Securities (USA) LLC ("TD Cowen") relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In

SOUTH SAN FRANCISCO, Calif. — SOUTH SAN FRANCISCO, Calif. — Alector Inc. on Thursday reported a loss of $22.9 million in its first quarter. On a per-share basis, the South San Francisco,...

Alector (NASDAQ:ALEC) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.35) by 40 percent. This is a 48.78 percent increase over losses of $(0.41) per share from the same

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes (ALKS) delivered earnings and revenue surprises of +30.31% and +9.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Alkermes (ALKS) delivered earnings and revenue surprises of +30.31% and +9.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Presenter SpeechPete Stavropoulos Hello, everyone. I'm Pete Stavropoulos, biotech analyst at Cantor with another webinar on the blood-brain barrier crossing technologies. It's an exciting time for

GSK (LSE:GSK) and Alector have discontinued their phase 2 trial of an Alzheimer's drug candidate after the study did not meet efficacy goals. The decision effectively ends a high profile collaboration in neurodegenerative research between the two companies. Separately, GSK received UK approval for Lynavoy (linerixibat) to treat primary biliary cholangitis. The company has also appointed Roanne Parry as Chief People Officer, a move that may shape its global people and culture agenda. GSK,...

GSK (LSE:GSK) and Alector have discontinued their phase 2 trial of an Alzheimer's drug candidate after the study did not meet efficacy goals. The decision effectively ends a high profile collaboration in neurodegenerative research between the two companies. Separately, GSK received UK approval for Lynavoy (linerixibat) to treat primary biliary cholangitis. The company has also appointed Roanne Parry as Chief People Officer, a move that may shape its global people and culture agenda. GSK,...

Alector’s refreshed analyst narrative comes with $6 price targets that are presented as more closely aligned with the company’s current therapeutic pipeline and BBB shuttle focus. Research notes link these $6 targets to a cleaner story after the frontotemporal dementia trial, with a stronger spotlight on neurodegeneration mechanisms and protein engineering strengths, alongside ongoing execution and clinical risks. As you read on, you will see how this evolving setup might shape your own view...

Alector’s refreshed analyst narrative comes with $6 price targets that are presented as more closely aligned with the company’s current therapeutic pipeline and BBB shuttle focus. Research notes link these $6 targets to a cleaner story after the frontotemporal dementia trial, with a stronger spotlight on neurodegeneration mechanisms and protein engineering strengths, alongside ongoing execution and clinical risks. As you read on, you will see how this evolving setup might shape your own view...

--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer’s disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson’s disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and metabolic disorders, alongside several first-in-class discovery programs— SOUTH SA

As April 2026 unfolds, the Middle East stock markets are experiencing a mixed yet cautiously optimistic phase, with most Gulf markets finishing higher despite lingering uncertainties over U.S.-Iran relations. This environment of cautious optimism provides a fertile ground for identifying undiscovered gems in the region's small-cap sector, where strong local fundamentals and strategic national initiatives could enhance growth potential.

As April 2026 unfolds, the Middle East stock markets are experiencing a mixed yet cautiously optimistic phase, with most Gulf markets finishing higher despite lingering uncertainties over U.S.-Iran relations. This environment of cautious optimism provides a fertile ground for identifying undiscovered gems in the region's small-cap sector, where strong local fundamentals and strategic national initiatives could enhance growth potential.